Top Page
Frontier IP
(LSE:FIPP)
Frontier IP (FIPP) vs. iShares MSCI United Kingdom ETF (EWC)
Frontier IP Business Overview & Revenue Model
Frontier IP Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 325.00K | 358.00K | 372.00K | 329.00K | 362.00K |
| Gross Profit | 291.00K | -1.42M | -1.15M | -1.39M | -1.17M |
| EBITDA | -6.25M | -3.33M | -2.89M | -3.04M | -2.07M |
| Net Income | -6.34M | -1.13M | -3.24M | 10.23M | 9.57M |
Balance Sheet | |||||
| Total Assets | 54.41M | 45.09M | 45.99M | 50.08M | 38.87M |
| Cash, Cash Equivalents and Short-Term Investments | 2.58M | 2.30M | 4.60M | 4.37M | 1.99M |
| Total Debt | 12.06M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 12.40M | 315.00K | 452.00K | 1.39M | 445.00K |
| Stockholders Equity | 42.00M | 44.77M | 45.54M | 48.70M | 38.42M |
Cash Flow | |||||
| Free Cash Flow | -3.50M | -2.83M | -3.26M | -3.01M | -1.48M |
| Operating Cash Flow | -3.46M | -2.81M | -3.25M | -3.01M | -1.47M |
| Investing Cash Flow | 420.00K | 370.00K | 3.38M | 5.38M | -1.69M |
| Financing Cash Flow | 3.33M | 136.00K | 98.00K | 0.00 | 2.18M |
Frontier IP Technical Analysis
Frontier IP Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | £124.33M | 37.44 | 1.79% | 3.29% | -9.37% | ― | |
63 Neutral | £798.61M | 7.44 | 8.92% | ― | 11.00% | ― | |
59 Neutral | £1.38B | 21.37 | 3.62% | 1.22% | -37.43% | -67.39% | |
52 Neutral | £16.22M | -6.05 | -14.80% | ― | 30.40% | 23.48% | |
50 Neutral | £503.55M | -3.97 | -14.23% | ― | ― | 33.10% | |
43 Neutral | £10.02M | -1.37 | -14.62% | ― | -9.22% | -386.93% |
Frontier IP Corporate Events
Frontier IP portfolio company The Vaccine Group has reported that its vaccine candidate against the zoonotic pig disease Streptococcus suis outperformed a leading commercial rival in challenge trials run by UK contract research organisation Moredun Scientific. The study showed that the firm’s bovine herpesvirus (BoHV-4) delivery platform is effective beyond cattle, works against both bacterial and viral pathogens, and can protect against multiple S. suis serotypes, reinforcing the broad applicability of its vaccine technology. The S. suis programme, which has benefited from collaborations in China and funding from Innovate UK, sits alongside a separate partnership with Spanish animal health group Syva on another S. suis vaccine, while The Vaccine Group is also in discussions with major animal health companies over commercial development of its bovine respiratory syncytial virus candidates for cattle, potentially strengthening Frontier IP’s position in the animal health innovation market.
The most recent analyst rating on (GB:FIPP) stock is a Sell with a £13.00 price target. To see the full list of analyst forecasts on Frontier IP stock, see the GB:FIPP Stock Forecast page.
Frontier IP Group plc has confirmed that its issued share capital consists of 75,638,239 ordinary shares of 10 pence each, with one voting right per share and no shares held in treasury, setting the total number of voting rights at the same figure. This updated capital and voting rights position provides the reference denominator for shareholders assessing whether they must disclose holdings or changes in interests under UK financial transparency rules, ensuring clarity for investors and regulators on the company’s current equity structure.
The most recent analyst rating on (GB:FIPP) stock is a Hold with a £15.00 price target. To see the full list of analyst forecasts on Frontier IP stock, see the GB:FIPP Stock Forecast page.
Frontier IP Group plc reported that all resolutions at its annual general meeting held on 31 December 2025 were duly passed, including approval of the audited accounts and directors’ remuneration for the year ended 30 June 2025. Shareholders backed the reappointment of all existing directors and the company’s auditor, and renewed authorities for the board to allot shares, disapply pre-emption rights in certain circumstances and make on-market share repurchases, signalling continued shareholder support for the current governance, capital structure flexibility and growth strategy.
The most recent analyst rating on (GB:FIPP) stock is a Hold with a £15.00 price target. To see the full list of analyst forecasts on Frontier IP stock, see the GB:FIPP Stock Forecast page.
Frontier IP Group plc has disclosed updated director shareholdings following the completion of a recent fundraising and retail offer, confirming the enlarged stakes held by its board members in the company’s ordinary shares. Chief executive Neil Crabb now holds 4.58 million shares, representing 6.05% of the enlarged share capital, while other executive and non-executive directors have also increased their holdings through participation in the subscription at 15.5 pence per share, signalling board-level confidence and further aligning management interests with those of shareholders.
Frontier IP Group has successfully completed an oversubscribed retail offer, raising £174,117 through the issue of 1,123,338 new shares at 15.5 pence each, as part of a wider fundraising that has conditionally generated approximately £1.04 million in gross proceeds. The additional capital, raised via a combination of placing, subscription and retail offer, will expand the company’s equity base to 75,638,239 ordinary shares, reinforcing its financial position as it pursues its IP commercialisation strategy, while the forthcoming admission of the new shares to trading on AIM on 24 December 2025 will broaden the shareholder base and may alter voting dynamics for existing investors under UK disclosure rules.
Frontier IP Group has highlighted a major boost for its portfolio company Dekiln Limited, after chief executive Dr Aled Roberts was named one of the Royal Academy of Engineering’s inaugural Green Future Fellows, bringing £3 million of funding to scale the firm’s kiln-free tile technology to industrial production. Dekiln, a Manchester-based clean-tech company that produces low-carbon, high-recycled-content tiles without energy-intensive kilns, plans to use the funds to build a pilot plant capable of producing up to 1,000m² of tiles per day in partnership with UK industrial partners, following a £693,000 equity raise in 2024 and its first commercial installation. The backing from the Royal Academy, part of a £39 million package for 13 fellows under a government-supported programme, is seen by Frontier IP as strong validation of Dekiln’s technology and is expected to accelerate the company’s scale-up, potentially enhancing Frontier IP’s portfolio value and reinforcing its positioning in climate-focused, resource-efficient industrial innovation.
Frontier IP Group plc has successfully raised approximately £870,000 through a combination of a share Placing and Subscription, with an additional Retail Offer expected to generate up to £174,117. This funding round is expected to bolster the company’s operational capabilities and further enhance its role in developing and commercializing intellectual property, reinforcing its position in the market.
Frontier IP Group plc has announced a conditional retail offer of new ordinary shares at a discounted price of 15.5 pence per share, available through RetailBook’s partner network. The offer aims to raise funds to support the company’s working capital and portfolio companies, with a minimum subscription of £250 per investor. The retail offer is part of a broader fundraising effort, including a placing and subscription by directors, to address the company’s financial needs and explore further funding opportunities in 2026. The company plans to review its cost base to enhance operational efficiency while maintaining growth momentum.
Frontier IP Group plc announced a proposed equity fundraising to raise approximately £870,000 through a combination of placing new ordinary shares and a subscription by the company’s directors. The fundraising aims to strengthen the company’s financial position amidst a challenging market environment, with the proceeds expected to support the continued development and commercialization of its portfolio companies. Despite recent financial setbacks, including unrealized losses and a reduced net asset value, the company remains optimistic about the progress and potential of its portfolio, which includes promising developments in sectors such as AI, defense, and energy conversion.
Frontier IP Group, which focuses on commercializing intellectual property, announced that its portfolio company Alusid Limited has raised £500,000 in a pre-IPO funding round, valuing the company at £10 million. The funds will be used to prepare for a potential IPO on AIM, expand product ranges, and develop Alusid’s low carbon tile manufacturing technology. Alusid is also broadening its market by developing new product categories and expanding its international distribution network, with growing demand for its sustainable tiles in both retail and commercial sectors.
Frontier IP Group plc has announced that its 2025 Annual Report and Accounts are now accessible on its website, with hard copies distributed to eligible shareholders. The company’s Annual General Meeting is scheduled for 31 December 2025 in Edinburgh, marking a significant event for stakeholders to discuss the company’s progress and future strategies.
Frontier IP Group plc reported its financial results for the year ending June 30, 2025, revealing a stable equity portfolio value but a significant reduction in its debt portfolio due to conversions and losses. The company experienced a substantial loss before tax driven by unrealized losses and operating expenses, despite raising £3.6 million for working capital and portfolio support. The strategic partnership with Abstract Mid-Tech Limited to create an innovation hub in Cambridge is expected to strengthen Frontier IP’s presence in the UK’s innovation sector and potentially generate positive cash flow. Several portfolio companies made significant progress, including successful funding rounds and international agreements, indicating strong technical and commercial advancements despite a challenging funding environment.
Alusid Limited, a portfolio company of Frontier IP Group, has signed an exclusive distribution agreement with Kakelspecialisten AB, a leading Swedish tile distributor and subsidiary of Saint-Gobain. This partnership marks Alusid’s third international agreement, enhancing its European distribution network and reflecting growing global interest in its sustainable tile products. The agreement grants Kakelspecialisten exclusive rights to distribute Alusid’s tiles in Sweden for 24 months, with non-exclusive rights for distribution outside Sweden. This collaboration aligns with Kakelspecialisten’s sustainability goals and strengthens Alusid’s position in the low-carbon tile market, potentially paving the way for further growth and an IPO.
Frontier IP Group Plc announced the departure of its Chief Financial Officer, Jo Stent, who is leaving to join a private equity-backed financial services provider. Stent will step down by April 2026, after overseeing the company’s annual and interim results. The company has begun the search for a new CFO, with updates to follow. CEO Neil Crabb expressed gratitude for Stent’s contributions, highlighting an amicable departure.
Frontier IP Group plc announced that its portfolio company, The Vaccine Group, has achieved significant success in animal trials with two vaccine candidates targeting bovine respiratory syncytial virus (BRSV). These vaccines, developed using a novel bovine herpesvirus delivery platform, have shown to effectively prevent BRSV in cattle, overcoming limitations of current vaccines that are ineffective in the presence of maternal antibodies. This breakthrough represents a major milestone for The Vaccine Group and positions its technology as a potential market leader in livestock disease prevention, with plans to engage strategic partners for further development.